

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61F 2/02, A61K 38/39	A1	(11) International Publication Number: WO 96/10374 (43) International Publication Date: 11 April 1996 (11.04.96)
(21) International Application Number: PCT/US94/11209 (22) International Filing Date: 3 October 1994 (03.10.94) (71) Applicant (for all designated States except US): OTOGEN CORPORATION [US/US]; 2454 Embarcadero Way, Palo Alto, CA 94303 (US). (72) Inventor; and (75) Inventor/Applicant (for US only): SIERRA, David, H. [US/US]; 48 Middle Gate, Atherton, CA 94027 (US). (74) Agents: ADLER, Reid, G. et al.; Morrison & Foerster, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US).		(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ). Published <i>With international search report.</i>
(54) Title: DIFFERENTIALLY BIODEGRADABLE BIOMEDICAL IMPLANTS (57) Abstract The current invention is a biomedical implant comprising a biomedical matrix material and a biodegradable porosifying agent. As the porosifying agent degrades in situ, an implant with an inter-connecting network is formed. The resultant mechanically stable implant allows for tissue and fluid influx into the matrix. The invention is also directed to a method for repair of mammalian tissue using the above-described implant.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LJ	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

5 DIFFERENTIALLY BIODEGRADABLE BIOMEDICAL IMPLANTSDescriptionTechnical Field

10 This invention is in the general field of biomaterials. More specifically, the invention is directed to biomedical implants, their composition and methods of preparation and use.

15 Background of the Invention

 Biomaterials have been used for implantation into the human body to act as supports for wound healing. Matrices useful for this purpose should have the ability to adhere and conform to the wound site and, ideally, facilitate accumulation of fibroblasts, endothelial cells and wound healing regulatory cells to promote connective tissue deposition and angiogenesis.

 U.S. Patent No. 4,849,285 to Dillon is directed to a composite, self-supporting agglomerated macrostructure useful as a surgical implant. The macrostructure is a matrix of polytetrafluoroethylene resin and cured silicone that has uniformly distributed within it a particulate material. These particulates have a maximum size of about 2000 microns and may be hydroxyapatite or tricalcium phosphate. This particular macrostructure, therefore, is a composite of ceramic particulate material and organic biomaterials that is uniformly permeated by a network of open pores. The pores are formed by incorporating sodium chloride into

the composite and thereafter leaching it out in the manufacturing process.

U.S. Patent No. 4,373,217 to Draenert is directed to a polymeric implant material that has an
5 acrylate, polymethacrylate or copolymer base with dispersed resorbable tricalcium phosphate of 50 to 300 microns with an available pore volume of less than 0.1 mL/g. This particular material is said to allow for a firm bond between implant and body tissue. Resorption of
10 tricalcium phosphate particles at the surface of the implant are resorbed into the body is said to promote bone growth in the marginal porosity produced. In order to ensure absorption of liquid monomer into the porous calcium phosphate, a filler that is also resorbable in
15 the body is included to fill the pore volumes of the calcium phosphate.

U.S. Patent No. 4,898,734 to Mathiowitz et al. also involves a precast solid polymeric implant material. A continuous polymeric matrix made of, for example,
20 polyurethane or polystyrene, is embedded with microcapsules or microspheres that may contain material for subsequent release. The spheres may be removed from the matrix by bioerosion. For creation of a vascular graft, erodible microspheres are entrapped within a tube-
25 shaped slower-degrading polymer matrix. Rapid erosion of the spheres results in pores for cell seeding and vascularization with the matrix providing support until there is sufficient cell growth to create structural integrity.

30 U.S. Patent No. 4,950,483 to Ksander et al. describes a collagen implant useful for wound healing. The implant is made of collagen and has a bulk density of 0.01 to 0.03 g/cm³ and is said to have a pore size sufficient to permit cell ingrowth. Bioactive agents

such as FGF and TGF- β may be incorporated into the implant.

U.S. Patent No. 5,077,049 to Dunn et al. is directed to a method for restoring periodontal tissue. A biodegradable liquid polymeric systems designed to generate a porous structure when cured into a barrier membrane, is administered to the soft-tissue defect. The pores will form as a result of water-soluble material included in the liquid material. The liquid material injected into the defect provides a scaffold that is filled with new bone cells that gradually replace the water-soluble polymer.

U.S. Patent No. 5,141,522 to Landi et al. describes a composite of two or more biocompatible polymers useful for mammalian tissue repair. One of the polymers is polytetrafluoroethylene (PTFE), which is the reinforcing binder. A bioabsorbable component that may be a lactone, carbonate or a lactide, is contained within the structure of the PTFE and serves to enhance ingrowth of tissue.

U. S. Patent No. 4,902,295 to Walthall et al. involves a transplantable artificial tissue. The tissue is made by polymerizing matrix and reversible gel precursors in an aqueous solution with viable cells. The gel, which may be alginate, a gum or agarose is then dissolved to provide a porous matrix for implantation.

None of the above-described references describes a biomedical implant material with a differentially degradable matrix and porosifying agent where polymerization occurs in situ or where the matrix is precast and is made of a biopolymeric or ceramic material.

Disclosure of the Invention

Accordingly, one aspect of the present invention is an in situ polymerizing biomedical implant useful for implantation into a patient comprising a
5 nonbiodegradable matrix material and a biodegradable porosifying agent.

Another aspect of the invention is a precast biomedical implant useful for implantation into a patient comprising a nonbiodegradable polymeric matrix or a
10 nonbiodegradable ceramic matrix and a biodegradable porosifying agent.

A further aspect of the invention is a method for repair of mammalian tissue using the above-described implants.

15

Modes of Carrying Out the Invention

Definitions

As used herein, certain terms will be used which have defined meanings.

20 By "biodegradable" or "bioerodible" is intended a material that will dissolve in situ as a result of exposure to an aqueous environment in less than a week, preferably about 1 and 72 hours, more preferably between about 2 and 12 hours. Dissolution may occur as a result
25 of a number of different mechanisms such as simple diffusion, hydrolysis, enzymatic cleavage, ion exchange, autocatalysis, osmosis, degradation, free-radical cleavage, radiation effect, thermal melting, and chemical dissolution. By "nonbiodegradable" or "nonbioerodible"
30 is intended a material that will not dissolve in situ (or in an aqueous environment) within a week, in fact the material may not dissolve in situ at all or may dissolve in a period of from about one week to 24 months, preferably a period of between about 1 to 12 months.

35

The term "porosifying agent" intends particulate materials that include but are not limited to materials in the form of solid or hollow spheres, extruded rods, or other convenient shapes. Typically, the particulate has a mean diameter of between about 10 and 500 μm , more typically between about 20 and 200 μg . The particles are generally spherical in shape but other shapes such as rhombic, irregular, stellate and other crystalline type shapes may be used. The agents are present in a concentration of at least about 12% per volume of the matrix material, preferably the concentration is between about 12 and 99% per volume of the matrix material, more preferably between about 20 and 90% per volume of the matrix material such that as the agent biodegrades a continuous porous network or pathway is formed within the implant.

The term "matrix" intends the portion of the implant material that acts as the support network, it is the slower biodegrading portion of the implant.

20

The Implant Material

This invention is to a biomedical implant comprising a non-toxic, nonbiodegradable biomedical matrix material and a non-toxic, biodegradable material that acts as a porosifying agent. The porosifying agent is present in sufficient quantity and particulate size to result in a continuous, porous network within the matrix once it has degraded.

The implant is biocompatible and is capable of solidifying when being cast or of solidifying and polymerizing in situ. Further, the matrix is nonbiodegradable as defined above and made from a material with a slower degradation rate than the porosifying agent. Degradation (or dissolution) rates of

35

particular substances in water are generally available information.

Examples of matrix materials include but are not limited to collagen, fibrin, fibrinogen, polyorthoesters, polyvinyl alcohol, polyurethanes, polyesters, polyvinyl alcohols, calcium or fluorophosphates, polyamino acids (e.g. polylysine, polyglutamic acid), metals, polyamides, polycarbonates, polyvinyl pyrrolidone, acrylates, and cyanoacrylates and combinations of the above.

The porosifying agent is biocompatible and biodegradable as described above. Examples of porosifying agents include but are not limited to gelatin, collagen, fibrin, fibrinogen, proteins in solid state like albumin powder, degradable polyesters (polylactic or polyglycolic acid), polyethylene glycol (PEG), ceramics, liposomes and alginates and combinations and derivatives of the above. The porosifying agents may be in a solid state, such that they dissolve over a period of time or may they may be altered such that they are in a sparingly soluble state. The may be accomplished for example by altering the pI, for example by methylation or succinylation or by conjugating the porosifying agent to polyethylene glycol (MW 1 to 50 Kd).

In addition to the matrix material and porosifying agent, the implants may further include growth factors including but not limited to epidermal growth factor (EGF), transforming growth factor β (TGF β -1, TGF β -2), platelet derived growth factor (PDGF-AA, PDGF-AB, PDGF-BB), fibroblast growth factor (FGF), insulin-like growth factors (IGF), tumor necrosis factors (TNF), colony stimulating factors (CSFs), nerve growth factors (NGF) and the like, and/or therapeutic agents including but not limited to cytokines, interleukins (IL-1, IL-2) or other co-factors such as heparin or

calmodulin, antibiotics, antineoplastic and antibacterials, to further stimulate or control tissue remodeling, or to control sepsis.

An important characteristic of the implant is that the porosifying agent degrades faster than the matrix material. For example, if fibrin is used as the matrix, then polyethylene glycol or gelatin, which degrade more rapidly in water (and thus in situ) than does fibrin, may be used as the porosifying agent. However, if fibrin is used as the porosifying agent, then collagen may be used as the matrix since it degrades more slowly than does fibrin.

Preparation of the Implant

In Situ Polymerizing Systems

In an in situ polymerization system, the porosifying agent may be mixed as a dry phase with the matrix which may be in a semi-solid, liquid or dry particulate phase. An appropriate catalyst or co-factor may be added to the mixture or the porosifying agent itself may contain such catalyst or co-factor that will initiate polymerization.

Fibrin sealants are an example of an in situ polymerizing system. Fibrin sealants are two component tissue adhesive systems that are in a relatively viscous liquid form until both components are mixed together and polymerize at the surgical application site into a relatively dense gel. Thrombin in combination with Ca^{2+} catalyzes the polymerization of fibrinogen, converting the fibrinogen into fibrin polymer. Further, thrombin and Ca^{2+} activate coagulation Factor XIII, which effects covalent crosslinking of fibrin. The rate of proteolytic degradation of the fibrin polymer clot is decreased and mechanical stability is increased as a result of the covalent crosslinking of the polymer.

The fibrin polymer clot is porous, but only at a range of 1 to 5 micron in mean diameter, too small to permit cellular ingrowth. Accordingly, macrophage activity is sustained over periods of time longer than optimal for degradation and remodeling, and the fibrin polymer clot acts as a barrier until phagocytosis is complete. Where a porosifying agent is added according to the present invention, tissue reunion is improved as a result of the continuous pathway formed in the clot when the porosifying agent degrades in situ.

For systems where the matrix is made of fibrin, particulates may be incorporated directly into the fibrinogen component which is obtained in lyophilized form. The particulates may be alginate, gelatin, polyethylene glycol, polylactic acid/polyglycolic acid (PLA/PGA) hollow spheres, hyaluronic acid and liposomes or other materials that degrade at a rate faster than the fibrin matrix and will create a continuous porous network once degraded. The porosifiers may be incorporated either in dry or liquid or semisolid form. Alternatively, the porosifier may be mixed just prior to, or during application of the system to the repair site.

In another embodiment, cyanoacrylate and methacrylate adhesives may be used as the matrix material of the inventive implants. The particulate is preferably a hydrophilic porosifier such as gelatin, collagen fibrin, a salt or polyethylene glycol. These implants are useful for repair of bone in that addition of the porosifying agents to the cyanoacrylate or methacrylate material improves the anchoring of the implant to surrounding bone. For example, in a methyl methacrylate system, the monomer is activated by free radicals which are formed by splitting of benzoyl peroxide. The rate of splitting is increased by addition of the N,N-dimethyl-p-toluidine co-factor. In another system, cyanoacrylate

adhesives are polymerized in situ by free radical polymerization activated by hydronium ions. In yet another system, marine adhesive protein is polymerized by a multi-step mechanism. The tyrosine residues are converted to dopa residues by tyrosinase. Cathecol oxidase then converts the dopa residues into quinone, which can complex crosslink with a wide variety of functional groups thereby effecting adhesion and cohesion of the implant.

Calcium alginates are another example of polymers which readily undergo in situ polymerization. Starting out as polymer chains in an aqueous solution, aggregation into a three-dimensional hydrogel occurs by complexing of the chains with divalent Ca^{2+} at a concentration of approximately 0.1M. Gelatin, fibrin or polyethylene glycol may be added as porosifying agents.

Pre-cast Systems

Alternatively, the matrix with the porosifying agent may be preformed and used for surgical reconstruction and drug delivery. In a particular embodiment, the implant is applied to the wound site as a dressing. The matrix material may be fibrin, alginate, collagen, PLA/PGA or other biocompatible polymers as well as rapidly dissolving ceramic based systems such as calcium sulfates, calcium phosphates, fluorophosphates and the like. Porosifying agents such as gelatin, fibrin, polyethylene glycol are added to the matrix material. Exudate from the repair site anchors the dressing in place by infiltrating the porous network produced as a result of the degrading particulate. Tissue adhesives including but not limited to materials such as fibrin sealants and occlusive wraps and tapes may help to anchor the dressings in place.

Use of the Implant

When the implant is placed or applied to a desired site in vivo, the porosifying agent biodegrades relatively rapidly, thus leaving behind an inter-
5 connecting network of pores to permit tissue and fluid influx into the matrix. The matrix then acts as a scaffolding for the migrating cells (e.g. macrophages, fibroblasts, and neovascular endothelial cells) and may either degrade as these cells express connective tissue
10 components for remodeling and regeneration or remain intact. In the case of nonbiodegradable matrix materials, the migrating cells form fibrous or even bony tissue to anchor the implant in place.

The use of a matrix with a component that
15 degrades in situ imparts several advantages over conventional porous implant configurations. First, porous implants tend to shrink in volume due to pressure from surrounding tissue, thus minimizing the benefits of controlled pore size and minimizing the amount of tissue
20 ingrowth that can take place. Where a porosifying agent that degrades in situ is added, however, the cells involved in wound healing migrate into the network and minimize shrinkage of the implant.

A further benefit of an in situ degrading
25 porosifying agent is that the porosifying agent acts as a mechanical stabilizer, permitting the formation of a porous network within the matrix. Materials such as gelatin, especially crosslinked gelatin, calcium alginate or fibrin are especially useful as the porosifying agent.
30 Crosslinking may be accomplished by the addition of agents such as SPEG (polyethylene glycol succinimide), glutaraldehyde, diisocyanate, or dehydrothermally. Where calcium alginate is the porosifying agent, the guluronic/mannuronic acid segment ratio may be optimized for in
35 vivo dissolution over the targeted period of time. Where

fibrin is the porosifying agent, a high quantity of plasmin (≥ 0.2 mg/mL) is also useful, permitting a degradation rate proportional to the quantity of plasminogen present. Where polyethylene glycol
5 particulate is used as the porosifying agent, a relatively rapid dissolution occurs (i.e. in less than 24 hours).

Another benefit derived from using an in situ biodegradable porosifying agent is that the mechanical
10 properties of the implant both pre- and post-polymerization can be altered, tailoring the viscosity of the applied material and improving its mechanical stability in situ. The porosifying agent increases the stiffness modulus of the implant while it is still
15 relatively undissolved. As dissolution occurs the contribution to the modulus by the porosifying agent decreases. Deposited ground substances (i.e. mucopolysaccharides, glycosaminoglycans, nectins and other proteoglycans) and collagen and inflammatory cells
20 are exchanged, thus the overall modulus status remains roughly the same throughout the life-span of the matrix.

The rate of degradation of the implant materials will vary depending upon the material used (PEG
25 the fastest, crosslinked gelatin the slowest) as well as the relative vascularity of the application site (liver, the fastest, subcutaneous, the slowest). A fibrin matrix will last usually from 5 to 14 days, depending upon concentration, plasminogen content and anatomic region.
30 Higher fibrin and lower plasmin concentrations will decrease degradation rates. The addition of antiproteases such as ϵ -amino-n-caproic acid or aprotinin will retard degradation further. Once the implant is applied to the wound site, the porosifying agent begins
35 to dissolve. This may occur in a matter of hours if the

agent is polyethylene glycol or a matter of days if calcium alginate. The resultant porosity permits firm anchoring to the wound bed by host fibrin clots intercalating through the porous network. Leukocytes, macrophages, lymphocytes and fibroblasts then migrate through the pores, breaking down the fibrin implant matrix and initiating deposition of ground tissue substances (e.g. proteoglycans) and collagen. By way of example, implants tailored to last for 7 to 14 days may be applied to donor graft beds, chronic decubitus ulcers, resected tumor sites or bone tissue gaps.

In situ polymerizing systems are introduced into the repair site by a variety of means. They may be poured onto the site directly or by a dispenser which permits control of the amount of material in the system, as well as the area covered. The implants may be used as occlusive or fluid tight dressings or sealants in anatomic regions where it would be difficult to use a precast dressing, such as in endoscopic procedures. An example of a dispensing device is the DUPLOJECT® fibrin sealant delivery device (Immuno AG, Vienna, Austria).

Precast systems may be used as occlusive dressings. They are ultimately integrated into the repair site and facilitate tissue remodelling. They may be suture, stapled, taped or wrapped into place. Generally, they are used as burn dressings or in tumor resection sites to facilitate reepithelialization. Also, they may deliver growth factors or antimicrobials (e.g., gentamicin, penicillin, silver ions) or other metabolic modulators (e.g. calcitonin, interleukins).

It is to be understood that while the invention has been described in conjunction with the preferred specific embodiments thereof, that the foregoing description as well as the examples that follow are

intended to illustrate and not limit the scope of the invention. Other aspects, advantages and modifications within the scope of the invention will be apparent to those skilled in the biomedical implant art.

5

Examples

Example 1 - Preparation of an In Situ Polymerizing Fibrin Implant

In a tuberculin syringe with a 20 gauge needle, concentrated fibrinogen-Factor XIII (60mg/mL) in tris-buffered saline (pH 7.2) is mixed with polyethylene glycol particulate (10000 MW, mean diameter 150 μ m) to 50 vol%.

Example 2 - Preparation of an In Situ Polymerizing Calcium Alginate Implant

Calcium alginate microspheres (mean diameter 100 μ m) prepared as described in Gospodarowicz and Cheng J. Cell Physiol 128:475-484 (1986) which is herein incorporated by reference in its entirety. These are added in a syringe to 50 vol% as described in Example 1.

Example 3 - Preparation of an In Situ Polymerizing Gelatin Implant

SPEG-crosslinked gelatin

5 mL of concentrated collagen slurry in phosphate buffered saline (pH 7.2, 35 mg/mL, Zyderm I, Collagen Corp, Palo Alto, CA) is heated to 60°C for 1 hour in a water bath, and then chilled to 37°C to produce gelatin. Phosphate-buffered saline is added to dilute the gelatin concentration to 15 mg/mL. Sufficient SPEG is added to the gelatin solution for a final concentration of 10 mg/mL. The gelatin-SPEG solution is allowed to cool to room temperature and gel. The gel is lyophilized and pulverized by a grinding mill. The

powder is sieved and particles in the range of 20 to 150 μm mean diameter are saved and sterilized by electron beam irradiation (2.5 Mrad dose).

5 The Matrix

The lyophilized SPEG crosslinked gelatin particulate is mixed with lyophilized fibrinogen-Factor XIII in a 1:1 v/v ratio. The powdered mixture is loaded into a dual plunger syringe system, containing both the
10 lyophilate and the reconstituting buffer, Tris buffered saline (TBS). To reconstitute the gelatin-fibrinogen mixture, the plunger is depressed, forcing the diluent into the chamber containing the lyophilate. After several minutes incubation, the resultant slurry is ready
15 to use.

Example 4- Preparation of a Pre-cast Fibrin Sealant System

12 vol % of polyethylene glycol particulate (MW
20 5kd with a mean diameter of 20 to 100 μm) is mixed with the fibrinogen solution at a concentration of 30 mg/mL. The mixture is then poured into a mold. Polymerization of the fibrinogen is catalyzed by the addition of thrombin and Ca^{2+} , usually in a 1:1 v/v ratio. The
25 catalyst is added rapidly and is thoroughly mixed to prevent settling of the particulate. 10 U/mL of thrombin is added for rapid polymerization. After gelling, the implant may be stored refrigerated (2-10°C) or frozen (-20 to -150°) until ready to use.

30

Example 5 - Preparation of an Pre-Cast Collagen System

5 mg/mL Collagen solution (Vitragen 100®, Celtrix Labs, Santa Clara, CA) is poured into a mold. Fibrin is added as the porosifying agent into the mold.
35 The same parameters as described in the previous example

apply for the porosifying agent in this example as well. For the collagen to gel, the pH is brought up to neutrality (pH7) by titration with concentrated phosphate buffered saline (PBS) and the temperature to 37°C by immersion in a water bath. The implant may be stored in the same manner as for the previous example.

Example 6 - Preparation of a Pre-cast Calcium Alginate System

Calcium alginate containing a minimum of 30% guluronic acid segments at 15 mg/mL in an aqueous solution is poured into a shallow rectangular mold. Gelatin is added as the porosifying agent at a concentration of 20 vol %. Concentrated calcium chloride solution is titrated rapidly into the alginate/gelatin mixture to a 0.1 M final concentration in the calcium alginate solution to effect gelling. Agitation of the mixture is necessary to minimize settling of the particulate. The implant is sterilized by quick exposure to a liquid bactericide (e.g. alcohol) and stored at temperatures as described above.

Modifications of the above-described modes for carrying out the invention that are obvious to those of skill in the fields of chemistry, materials science, medicine and related fields are intended to be within the scope of the following claims.

30

35

Claims

I claim:

1. A differentially biodegradable biomedical
implant useful for implantation into a patient
5 comprising:
a nonbiodegradable biocompatible matrix
material; and
a biodegradable biocompatible porosifying
agent,
10 wherein polymerization and solidification of
said implant occurs in situ and wherein, upon degradation
of the porosifying agent, a continuous porous network is
formed within the implant.
- 15 2. The implant of claim 1 wherein the
porosifying agent is in particulate form.
3. The implant of claim 1 wherein the
porosifying agent is selected from the group consisting
20 of gelatin, collagen, fibrin, fibrinogen, proteins,
degradable polyesters, polyethylene glycols, antibiotics,
silver compounds, ceramics, encapsulated cytokines,
liposomes and alginates and derivatives thereof.
- 25 4. The implant of claim 1 wherein the matrix
is selected from the group consisting of gelatin,
collagen, fibrin, fibrinogen, polyorthoesters, polyvinyl
alcohol, polyurethanes, calcium phosphates,
fluorophosphates, metals, methacrylates, and
30 cyanoacrylates and mixtures thereof.
5. The implant of claim 1 further comprising
a growth factor.

6. The implant of claim 5 wherein the growth factor is selected from the group consisting of TGF β -1, TGF β -2, FGF, EGF, PDGF-AA, PDGF-AB, PDGF-BB, IGF, TNF, CSF, and NGF.

5

7. The implant of claim 1 further comprising a therapeutic agent.

8. The implant of claim 7 wherein the
10 therapeutic agent is selected from the group consisting of cytokines, interleukins, heparin, calmodulin, antibiotics, antineoplastics and antibacterials.

9. A differentially biodegradable biomedical
15 implant useful for implantation into a patient comprising:

a nonbiodegradable fibrin matrix material; and
a biodegradable polyethylene glycol porosifying
agent,

20 wherein polymerization and solidification of said implant occurs in situ and where upon degradation of the polyethylene glycol, a continuous porous network is formed within the implant.

25 10. A differentially biodegradable precast biomedical implant useful for implantation into a patient comprising:

a nonbiodegradable biocompatible matrix
material comprising a biopolymeric or a ceramic material;
30 and

a biodegradable biocompatible porosifying
agent,

35 wherein upon degradation of the porosifying agent, a continuous porous network is formed within the implant.

11. The implant of claim 10 wherein the porosifying agent is in particulate form.

5 12. The implant of claim 10 wherein the porosifying agent is selected from the group consisting of gelatin, collagen, fibrin, fibrinogen, proteins, degradable polyesters, antibiotics, silver compounds, encapsulated cytokines, liposomes and alginates.

10 13. The implant of claim 10 wherein the matrix is selected from the group consisting of gelatin, collagen, fibrin, fibrinogen, calcium phosphates and fluorophosphates.

15 14. The implant of claim 10 further comprising a growth factor.

20 15. The implant of claim 14 wherein the growth factor is selected from the group consisting of $TGF\beta$ -1, $TGF\beta$ -2, FGF, EGF, PDGF-AA, PDGF-AB, PDGF-BB, IGF, TNF, CSF, and NGF.

25 16. The implant of claim 10 further comprising a therapeutic agent.

30 17. The implant of claim 16 wherein the therapeutic agent is selected from the group consisting of cytokines, interleukins, heparin, calmodulin, antibiotics, antineoplastics and antibacterials.

35 18. A method for repair of tissue comprising introducing a differentially biodegradable biomedical implant into the tissue repair site, said implant comprising:

-19-

a nonbiodegradable biocompatible matrix material; and

a biodegradable biocompatible porosifying agent;

5 wherein polymerization and solidification of said implant occurs in situ, and wherein, upon degradation of the porosifying agent, a continuous porous network is formed within the implant.

10 19. A method for repair of tissue comprising introducing a differentially biodegradable precast biomedical into the tissue repair site, said implant comprising:

15 a nonbiodegradable biocompatible matrix material comprising a biopolymeric or ceramic material; and

a biodegradable biocompatible porosifying agent,

20 wherein upon degradation of the porosifying agent, a continuous porous network is formed within the implant.

25

30

35

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US94/11209

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61F 2/02; A61K 38/39

US CL : 424/423, 424, 426, 450

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/423, 424, 426, 450

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US, A, 5,292,802 (RHEE ET AL.) 08 March 1994, see columns 5-8.	1-19

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	* T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
* A		document defining the general state of the art which is not considered to be part of particular relevance
* E		earlier document published on or after the international filing date
* L		document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
* O		document referring to an oral disclosure, use, exhibition or other means
* P		document published prior to the international filing date but later than the priority date claimed
	* X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
	* Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
	* A	document member of the same patent family

Date of the actual completion of the international search

08 FEBRUARY 1995

Date of mailing of the international search report

13 MAR 1995

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

Carlos Azpuru
Carlos Azpuru

Telephone No. (703) 308-2351